What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose”In the company’s words, NCT07324850 on ClinicalTrials.gov
- Tested for
- Obesity & Overweight
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.”In the company’s words, NCT07324850 on ClinicalTrials.gov
Other drugs for Obesity & Overweight
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 28 Oct 2026 | A Study of SGB-7342 in Subjects With Obesity or Overweight |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026